

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/628,475	07/29/2003	Joseph D. Artiss	AJC 201.1 US/10304772	4686
7	590 09/02/2004		EXAM	INER
Mary Anne Schofield			FUBARA, BLESSING M	
Fulbright & Jaworski L.L.P. 801 Pennsylvania Avenue, N.W.		ART UNIT	PAPER NUMBER	
Washington, DC 20004			1615	
			DATE MAIL ED. 00/02/200	

DATE MAILED: 09/02/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

- 3						
	Application No.	Applicant(s)				
	10/628,475	ARTISS ET AL.				
Office Action Summary	Examiner	Art Unit				
	Blessing M. Fubara	1615				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1: after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of the period for reply within the set or extended period for reply will, by statute the period of the	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 24 D	<u>ecember 2003</u> .	•				
2a) This action is FINAL . 2b) This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ☐ Claim(s) 13-116 is/are pending in the application 4a) Of the above claim(s) is/are withdraw 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) 13-116 is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) are subject to restriction and/or	vn from consideration.					
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct	epted or b) objected to by the l drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119	,					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applicati rity documents have been receive u (PCT Rule 17.2(a)).	ion No ed in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 122/2/03 &06/10/04.	4) Interview Summary Paper No(s)/Mail Do 5) Notice of Informal F 6) Other:					

DETAILED ACTION

Examiner acknowledges receipt of preliminary amendment and remarks filed 12/22/03 and 12/24/03; petition filed 12/24/03; IDS filed 12/22/03 and 06/10/04. The petition to make special was granted.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter, which the applicant regards as his invention.

3. Claim 80 is rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for reducing fat, does not reasonably provide enablement for preventing fat absorption. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. To "prevent" is to keep from happening.

For rejections under 35 U.S.C. 112, first paragraph, the following factors are considered (<u>In re Wands</u>, 8 USPQ2d 1400, 1404 (CAFC, 1988):

- I) Nature of invention.
- II) State of prior art.
- III) Level of ordinary skill in the art.
- IV) Level of predictability in the art.

Application/Control Number: 10/628,475 Page 3

Art Unit: 1615

V) Amount of direction and guidance provided by the inventor.

VI) Quantity of experimentation needed to make or use the invention based on the content of the disclosure.

I. Nature of the invention:

The claims are drawn to method for reducing the bioavailability of fat in a fat containing food product by complexing the amount of fat in the food product with α -cyclodextrin. Applicants' specification does not discuss or show with data how the recurrence of migraine has been kept from happening.

II. State of the prior art:

The prior art does not disclose case supported by data showing that absorption of fat in or by a subject has been kept from happening and how long the fat has been kept from being absorbed by a subject in how many subjects has the absorption of fat been stopped or kept form happening.

III. Level of Ordinary Skill in the art:

The level of ordinary skill in the art is high. Applicants' specification does not enable the public to practice the art of keeping fat from being absorbed.

IV. Level of predictability:

Since applicants' specification does not show the stoppage or exclusion or keeping fatabsorption from taking place and for how long a subject is kept from absorbing fat, the ability of the person of skill in the art is challenged to extrapolate the disclosed or known results to the claimed invention with little or no predictability. The lower the predictability, the higher the direction and guidance that must be provided by the applicants. In the instant invention the Application/Control Number: 10/628,475

Art Unit: 1615

predictability is very low and consequently, the need for the higher levels of direction and guidance by the applicants.

V. <u>Amount of direction and guidance provided by the inventors</u>:

The amount of direction and guidance provided by the applicants is limited to complexing α -cyclodextrin with fat. There is no evidence in the specification that established correlation between administration of fat α -cyclodextrin complexed food product and keeping fat from being absorbed. See Ex parte Mass, 9 USPQ2d 1746, 1987.

VI. Quantity of experimentation needed to make or use the invention based on the content of the disclosure:

The quantity of experimentation required to use the invention as claimed, based on applicants' disclosure would be undue burden because, one of ordinary skill in the art would have to perform significant amount of experimentation with a large number of subjects and for reliable duration of time during which fat is stopped or kept from being absorbed by a subject.

4. Claims 13-17, 62-76, 80 and 81 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 13 is not clear. It appears that α -cyclodextrin should be α -cyclodextrin-fat-complex since the α -cyclodextrin forms a complex with the fat. The fat is in excess and there will not be any cyclodextrin left for removal.

Claim 17 is directed to combining α -cyclodextrin and fat and the cyclodextrin is in the form of a pill, tablet, powder, capsule, liquid, cracker, wafer or confection. It is not clear how the pill, tablet or capsule is mixed or combined with the food.

Application/Control Number: 10/628,475 Page 5

Art Unit: 1615

Claim 80 is confusing because the claim is not clear as to what the claim is directed to.

Claim Rejections - 35 USC § 103

- 5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 6. Claims 13-116 are rejected under 35 U.S.C. 103(a) as being unpatentable over Suzuki et al. (JP 6094912, provided by applicants on PTO Form 1449).

Suzuki discloses compositions that are administered to subjects to reduce fat and the composition comprises α -cylodextrin present in amounts of 10-40%. Suzuki does not determine the amount of fast contained in the food before administering the α -cylodextrin. Regarding the forming of cyclodextrin-fat complex, it is inherent that a complex would form when α -cylodextrin come in contact with a fat. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made to administer the composition of Suzuki to reduce fat. One having ordinary skill in the would have been motivated to administer α -cylodextrin to a subject in need thereof with the expectation of reducing fat.

Drawings

7. The drawings are objected to as failing to comply with 37 CFR 1.84; copy of Patent Drawing Review.

Other Matters:

Seafood and fish sticks are generally not considered as a meat product. It is not clear what makes up the deli slices. French fries and nut butters are listed as vegetables and generally

Application/Control Number: 10/628,475

Art Unit: 1615

these food items are not listed as vegetables. Claims 91-94 recite "before or during consumption of a meal." It appears that the α -cylodextrin is consumed before a meal or is taken with the meal. The claims may be amended to recite ---consumed before a meal or with the meal---.

8. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicants' cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 3:30 p.m. (Monday to Friday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on (571) 272-0602. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Blessing Fubara Albara Patent Examiner

Patent Examiner Tech. Center 1600